Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems Inc. (NYSE: VEEV) is a cloud software company focused on the global life sciences industry, and its news flow reflects activity across commercial, R&D, quality, and corporate initiatives. Company announcements frequently highlight new product capabilities in its industry cloud for life sciences, including developments in Veeva AI, Vault CRM, Veeva Development Cloud, Veeva Quality Cloud, and solutions such as Veeva Environmental Monitoring and Veeva Basics.
Investors and industry professionals following VEEV news can see updates on strategic partnerships with major life sciences companies, such as long-term enterprise agreements and expanded use of Vault CRM by large pharmaceutical and biopharmaceutical organizations. Veeva also issues releases on its work with emerging biotechs, including adoption of Veeva Basics to standardize operations across clinical, regulatory, and quality.
Veeva’s news includes information on AI-driven capabilities like Veeva AI Agents for Vault CRM and PromoMats, covering agents such as Free Text Agent, Voice Agent, Pre-call Agent, Quick Check Agent, and Content Agent. These updates describe how the company embeds industry-specific AI into its applications to support productivity, compliance, and customer engagement in life sciences.
In addition, Veeva regularly publishes earnings results, financial outlooks, and capital allocation decisions, such as the authorization of a share repurchase program reported in an 8-K filing. The company also announces participation in investor conferences and provides details on its role as a Public Benefit Corporation. This news page aggregates these releases so readers can track product milestones, customer agreements, AI developments, financial updates, and corporate governance disclosures related to VEEV.
The United States District Court for the Southern District of New York dismissed Medidata's trade secret misappropriation lawsuit against Veeva Systems (NYSE: VEEV) on July 15, 2022, ruling that Medidata failed to substantiate its claims. This ruling is pivotal for protecting employee rights and promoting competition in the life sciences sector. The court's decision highlighted that Medidata's lawsuit was an attempt to stifle innovation and intimidate employees. The dismissed suit has reportedly cost both companies about $40 million over five years.
ANI Pharmaceuticals and Veeva Systems have partnered to enhance commercial strategies for ANI's Rare Disease Business Unit, utilizing Veeva's data-driven tools. This collaboration aims to launch ANI's first product, Purified Cortrophin Gel, in the U.S. The companies emphasize agility and precision in addressing rare disease patients' needs. ANI has adopted Veeva Commercial Cloud solutions to strengthen its sales and marketing capabilities. This partnership is expected to refine customer engagement and optimize sales interactions, marking a significant step in ANI's mission to improve patient access.
Veeva Systems recently introduced Veeva Vault Study Training, a new application designed to unify learning management and clinical operations for enhanced clinical study training. This platform allows research sites, CROs, and sponsors to train trial staff efficiently and maintain real-time inspection readiness by automating training certificate filing. The application, available to early adopters in fall 2022, aims to streamline study execution and compliance, leveraging existing clinical data to minimize redundancy and manual tasks.
Veeva Systems (NYSE: VEEV) announced that over 200 organizations are leveraging Veeva Vault Training for role-based training and qualification management. With over 13 million training assignments completed, the platform drives an average of 11,000 daily learner views. Recent enhancements include form-based evaluations and an extensive eLearning library with 170 courses. This growth in adoption highlights Veeva's commitment to streamlining training for the life sciences sector, addressing workforce efficiency and compliance challenges.
Veeva Systems Inc. reported strong fiscal Q1 2023 results, with total revenues reaching $505.1 million, a 16% increase year-over-year. Subscription services revenues also grew by 18% to $402.6 million. Despite a slight decline in operating income to $127.7 million, non-GAAP operating income increased by 10% to $199.6 million. Net income fell 13% to $100.1 million, whereas non-GAAP net income rose 9% to $159.8 million. The company maintains a positive outlook, forecasting total revenues between $2,165 and $2,175 million for the fiscal year, aided by innovations and expanding customer engagement.
Veeva Systems (NYSE: VEEV) announced significant adoption of its Vault CTMS, with over 150 companies utilizing the platform to manage clinical trial operations. The system supports more than 300,000 research sites and 1 million patients, enhancing productivity and data quality. Innovations like risk-based study management and improved site monitoring features are streamlining trial processes, allowing for faster execution. With three product releases annually, Veeva aims to further improve clinical operations and accelerate drug development.
At the Veeva Commercial Summit, Veeva Systems (NYSE: VEEV) released the 2022 Trends in Health Advertising Report, highlighting a 61% increase in digital audio impressions and an 18% rise in streaming video impressions in healthcare advertising. The report, based on over $6 billion in advertising investments, shows that digital audio campaigns, particularly in categories like women's health, were 120% more effective than traditional display ads. The study emphasizes the importance of diversifying media strategies to enhance effectiveness and reach among healthcare professionals and patients.
Veeva Systems (NYSE: VEEV) will announce its fiscal 2023 first quarter financial results on June 1, 2022, after market close. A conference call to discuss these results will be held at 2:00 p.m. PT (5:00 p.m. ET) on the same day. Prepared remarks will be available on their investor relations website at approximately 1:05 p.m. PT (4:05 p.m. ET). Veeva continues to lead in cloud software for the life sciences sector, serving over 1,000 customers, from large pharmaceutical companies to emerging biotechs.
On May 4, 2022, Veeva Systems announced that Lucid Diagnostics Inc. has selected Veeva Vault CDMS for its upcoming study on EsoGuard, aimed at detecting Barrett's esophagus and esophageal adenocarcinoma in at-risk patients. This multicenter study will gather real-world data using EsoGuard testing on samples collected with EsoCheck. Veeva aims to support the medtech sector with its unified data management solutions, enhancing study efficiency. The partnership reflects Veeva's commitment to innovation in clinical trials.
On May 3, 2022, Veeva Systems (NYSE: VEEV) announced that AmplifyBio will utilize its Veeva Vault Quality Suite to enhance quality management in preclinical drug testing. This collaboration aims to streamline processes and ensure compliance with stringent GLP requirements, facilitating better data generation for FDA submissions. AmplifyBio, a CRO specializing in toxicology and safety pharmacology, will leverage various Veeva products to manage quality consistently across its operations. The initiative underscores Veeva's commitment to supporting advancements in the life sciences sector.